Kendra K Radtke

6PUBLICATIONS
19CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Disease surveillancePharmacogenomicsMedical virologyInfant and child health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Nov 18, 2024
Clinical Pharmacology of Cytokine Release Syndrome with T-Cell-Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies.

Kendra K Radtke, Brendan C Bender, Zao Li

|Feb 12, 2024
Predictive Modeling of Drug-Related Adverse Events with Real-World Data: A Case Study of Linezolid Hematologic Outcomes.

Anu Patel, Sarah B Doernberg, Travis Zack

|Jun 26, 2023
QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies.

Ali Mohamed Ali, Kendra K Radtke, Anneke C Hesseling

|Oct 04, 2021
Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study.

Kendra K Radtke, Jacqueline P Ernest, Nan Zhang

|Jul 21, 2021
Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children.

Kendra K Radtke, Anneke C Hesseling, J L Winckler

|Jul 25, 2020
Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children.

Kendra K Radtke, Jennifer E Hibma, Anneke C Hesseling

Pageof 1

Frequent Collaborators

2 joint publications

Rada M Savic

1 joint publications

Jacqueline P Ernest

1 joint publications

Nan Zhang

1 joint publications

Nicole C Ammerman